nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A7—Simvastatin—atherosclerosis	0.0573	0.0803	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0573	0.0803	CbGbCtD
Ondansetron—CYP3A7—Lovastatin—atherosclerosis	0.056	0.0786	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.056	0.0786	CbGbCtD
Ondansetron—CYP3A5—Rosuvastatin—atherosclerosis	0.0462	0.0648	CbGbCtD
Ondansetron—CYP3A5—Simvastatin—atherosclerosis	0.043	0.0603	CbGbCtD
Ondansetron—CYP3A5—Pravastatin—atherosclerosis	0.042	0.059	CbGbCtD
Ondansetron—CYP3A5—Lovastatin—atherosclerosis	0.042	0.059	CbGbCtD
Ondansetron—CYP2D6—Niacin—atherosclerosis	0.0333	0.0468	CbGbCtD
Ondansetron—CYP2C9—Rosuvastatin—atherosclerosis	0.031	0.0435	CbGbCtD
Ondansetron—CYP2C9—Simvastatin—atherosclerosis	0.0288	0.0404	CbGbCtD
Ondansetron—CYP2C9—Pravastatin—atherosclerosis	0.0282	0.0396	CbGbCtD
Ondansetron—CYP2C9—Lovastatin—atherosclerosis	0.0282	0.0396	CbGbCtD
Ondansetron—CYP2D6—Simvastatin—atherosclerosis	0.0263	0.037	CbGbCtD
Ondansetron—CYP2D6—Lovastatin—atherosclerosis	0.0258	0.0362	CbGbCtD
Ondansetron—CYP2D6—Pravastatin—atherosclerosis	0.0258	0.0362	CbGbCtD
Ondansetron—CYP3A4—Rosuvastatin—atherosclerosis	0.018	0.0253	CbGbCtD
Ondansetron—CYP3A4—Ezetimibe—atherosclerosis	0.018	0.0253	CbGbCtD
Ondansetron—CYP3A4—Simvastatin—atherosclerosis	0.0168	0.0235	CbGbCtD
Ondansetron—CYP3A4—Lovastatin—atherosclerosis	0.0164	0.023	CbGbCtD
Ondansetron—CYP3A4—Pravastatin—atherosclerosis	0.0164	0.023	CbGbCtD
Ondansetron—Sleep disturbance—Pravastatin—atherosclerosis	0.00242	0.013	CcSEcCtD
Ondansetron—Foetor hepaticus—Pravastatin—atherosclerosis	0.00239	0.0128	CcSEcCtD
Ondansetron—Liver disorder—Ezetimibe—atherosclerosis	0.00231	0.0124	CcSEcCtD
Ondansetron—Liver disorder—Simvastatin—atherosclerosis	0.0022	0.0118	CcSEcCtD
Ondansetron—Laryngeal oedema—Niacin—atherosclerosis	0.00214	0.0115	CcSEcCtD
Ondansetron—Redness—Niacin—atherosclerosis	0.00204	0.0109	CcSEcCtD
Ondansetron—Liver disorder—Pravastatin—atherosclerosis	0.00199	0.0107	CcSEcCtD
Ondansetron—Laryngospasm—Niacin—atherosclerosis	0.00184	0.00988	CcSEcCtD
Ondansetron—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00184	0.00986	CcSEcCtD
Ondansetron—Feeling hot—Niacin—atherosclerosis	0.00175	0.0094	CcSEcCtD
Ondansetron—Musculoskeletal pain—Lovastatin—atherosclerosis	0.00162	0.00869	CcSEcCtD
Ondansetron—Sleep disorder—Rosuvastatin—atherosclerosis	0.00159	0.0085	CcSEcCtD
Ondansetron—Hepatocellular injury—Ezetimibe—atherosclerosis	0.00157	0.00842	CcSEcCtD
Ondansetron—Hepatic failure—Rosuvastatin—atherosclerosis	0.00153	0.00818	CcSEcCtD
Ondansetron—Hepatocellular injury—Simvastatin—atherosclerosis	0.0015	0.00803	CcSEcCtD
Ondansetron—Musculoskeletal pain—Pravastatin—atherosclerosis	0.00137	0.00735	CcSEcCtD
Ondansetron—Hepatocellular injury—Pravastatin—atherosclerosis	0.00136	0.00726	CcSEcCtD
Ondansetron—Hepatic failure—Lovastatin—atherosclerosis	0.00129	0.00694	CcSEcCtD
Ondansetron—Hepatic failure—Ezetimibe—atherosclerosis	0.00127	0.0068	CcSEcCtD
Ondansetron—Sleep disorder—Simvastatin—atherosclerosis	0.00126	0.00674	CcSEcCtD
Ondansetron—Swelling—Simvastatin—atherosclerosis	0.00123	0.00661	CcSEcCtD
Ondansetron—Hepatic failure—Simvastatin—atherosclerosis	0.00121	0.00649	CcSEcCtD
Ondansetron—Atrial fibrillation—Simvastatin—atherosclerosis	0.00115	0.00615	CcSEcCtD
Ondansetron—Sleep disorder—Pravastatin—atherosclerosis	0.00114	0.00609	CcSEcCtD
Ondansetron—Hepatic failure—Pravastatin—atherosclerosis	0.00109	0.00587	CcSEcCtD
Ondansetron—Atrial fibrillation—Niacin—atherosclerosis	0.00105	0.00565	CcSEcCtD
Ondansetron—Liver function test abnormal—Ezetimibe—atherosclerosis	0.00105	0.00564	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.00105	0.00561	CcSEcCtD
Ondansetron—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00103	0.00551	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.00103	0.00551	CcSEcCtD
Ondansetron—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.001	0.00536	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00098	0.00525	CcSEcCtD
Ondansetron—Urinary retention—Niacin—atherosclerosis	0.00095	0.00509	CcSEcCtD
Ondansetron—Liver function test abnormal—Niacin—atherosclerosis	0.000923	0.00494	CcSEcCtD
Ondansetron—Liver function test abnormal—Pravastatin—atherosclerosis	0.000908	0.00487	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000889	0.00476	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.000886	0.00475	CcSEcCtD
Ondansetron—Urinary tract infection—Lovastatin—atherosclerosis	0.000871	0.00467	CcSEcCtD
Ondansetron—Arrhythmia—Rosuvastatin—atherosclerosis	0.000848	0.00455	CcSEcCtD
Ondansetron—Angina pectoris—Niacin—atherosclerosis	0.000841	0.00451	CcSEcCtD
Ondansetron—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000832	0.00446	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000831	0.00445	CcSEcCtD
Ondansetron—Angina pectoris—Pravastatin—atherosclerosis	0.000828	0.00444	CcSEcCtD
Ondansetron—Flatulence—Rosuvastatin—atherosclerosis	0.000815	0.00436	CcSEcCtD
Ondansetron—Dysuria—Pravastatin—atherosclerosis	0.000795	0.00426	CcSEcCtD
Ondansetron—Erythema multiforme—Lovastatin—atherosclerosis	0.000761	0.00408	CcSEcCtD
Ondansetron—Angioedema—Rosuvastatin—atherosclerosis	0.000755	0.00405	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000752	0.00403	CcSEcCtD
Ondansetron—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000747	0.004	CcSEcCtD
Ondansetron—Flushing—Lovastatin—atherosclerosis	0.000747	0.004	CcSEcCtD
Ondansetron—Erythema multiforme—Ezetimibe—atherosclerosis	0.000746	0.004	CcSEcCtD
Ondansetron—Myocardial infarction—Pravastatin—atherosclerosis	0.000743	0.00398	CcSEcCtD
Ondansetron—Urinary tract infection—Pravastatin—atherosclerosis	0.000737	0.00395	CcSEcCtD
Ondansetron—Flushing—Ezetimibe—atherosclerosis	0.000733	0.00393	CcSEcCtD
Ondansetron—Chills—Lovastatin—atherosclerosis	0.000722	0.00387	CcSEcCtD
Ondansetron—Cough—Rosuvastatin—atherosclerosis	0.000721	0.00387	CcSEcCtD
Ondansetron—Angiopathy—Ezetimibe—atherosclerosis	0.000716	0.00384	CcSEcCtD
Ondansetron—Immune system disorder—Ezetimibe—atherosclerosis	0.000713	0.00382	CcSEcCtD
Ondansetron—Erythema multiforme—Simvastatin—atherosclerosis	0.000712	0.00381	CcSEcCtD
Ondansetron—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000711	0.00381	CcSEcCtD
Ondansetron—Flushing—Simvastatin—atherosclerosis	0.000699	0.00374	CcSEcCtD
Ondansetron—Haemoglobin—Niacin—atherosclerosis	0.000695	0.00372	CcSEcCtD
Ondansetron—Haemorrhage—Niacin—atherosclerosis	0.000691	0.0037	CcSEcCtD
Ondansetron—Flatulence—Lovastatin—atherosclerosis	0.00069	0.0037	CcSEcCtD
Ondansetron—Erythema—Ezetimibe—atherosclerosis	0.000687	0.00368	CcSEcCtD
Ondansetron—Flatulence—Ezetimibe—atherosclerosis	0.000677	0.00363	CcSEcCtD
Ondansetron—Chills—Simvastatin—atherosclerosis	0.000675	0.00362	CcSEcCtD
Ondansetron—Visual impairment—Niacin—atherosclerosis	0.000666	0.00357	CcSEcCtD
Ondansetron—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000662	0.00355	CcSEcCtD
Ondansetron—Vision blurred—Lovastatin—atherosclerosis	0.00066	0.00354	CcSEcCtD
Ondansetron—Tremor—Lovastatin—atherosclerosis	0.000656	0.00352	CcSEcCtD
Ondansetron—Visual impairment—Pravastatin—atherosclerosis	0.000656	0.00351	CcSEcCtD
Ondansetron—Erythema—Simvastatin—atherosclerosis	0.000655	0.00351	CcSEcCtD
Ondansetron—Ill-defined disorder—Lovastatin—atherosclerosis	0.00065	0.00348	CcSEcCtD
Ondansetron—Eye disorder—Niacin—atherosclerosis	0.000646	0.00346	CcSEcCtD
Ondansetron—Flatulence—Simvastatin—atherosclerosis	0.000646	0.00346	CcSEcCtD
Ondansetron—Erythema multiforme—Pravastatin—atherosclerosis	0.000644	0.00345	CcSEcCtD
Ondansetron—Flushing—Niacin—atherosclerosis	0.000642	0.00344	CcSEcCtD
Ondansetron—Angioedema—Lovastatin—atherosclerosis	0.00064	0.00343	CcSEcCtD
Ondansetron—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000638	0.00342	CcSEcCtD
Ondansetron—Malaise—Lovastatin—atherosclerosis	0.000632	0.00339	CcSEcCtD
Ondansetron—Flushing—Pravastatin—atherosclerosis	0.000632	0.00338	CcSEcCtD
Ondansetron—Cardiac disorder—Pravastatin—atherosclerosis	0.000632	0.00338	CcSEcCtD
Ondansetron—Angioedema—Ezetimibe—atherosclerosis	0.000628	0.00336	CcSEcCtD
Ondansetron—Angiopathy—Niacin—atherosclerosis	0.000627	0.00336	CcSEcCtD
Ondansetron—Chills—Niacin—atherosclerosis	0.00062	0.00332	CcSEcCtD
Ondansetron—Malaise—Ezetimibe—atherosclerosis	0.00062	0.00332	CcSEcCtD
Ondansetron—Vision blurred—Simvastatin—atherosclerosis	0.000618	0.00331	CcSEcCtD
Ondansetron—Arrhythmia—Niacin—atherosclerosis	0.000618	0.00331	CcSEcCtD
Ondansetron—Tremor—Simvastatin—atherosclerosis	0.000614	0.00329	CcSEcCtD
Ondansetron—Chills—Pravastatin—atherosclerosis	0.000611	0.00327	CcSEcCtD
Ondansetron—Ill-defined disorder—Simvastatin—atherosclerosis	0.000608	0.00326	CcSEcCtD
Ondansetron—Arrhythmia—Pravastatin—atherosclerosis	0.000608	0.00326	CcSEcCtD
Ondansetron—Palpitations—Ezetimibe—atherosclerosis	0.000607	0.00325	CcSEcCtD
Ondansetron—Paraesthesia—Rosuvastatin—atherosclerosis	0.000606	0.00325	CcSEcCtD
Ondansetron—Erythema—Niacin—atherosclerosis	0.000602	0.00322	CcSEcCtD
Ondansetron—Cough—Ezetimibe—atherosclerosis	0.0006	0.00321	CcSEcCtD
Ondansetron—Angioedema—Simvastatin—atherosclerosis	0.000599	0.00321	CcSEcCtD
Ondansetron—Chest pain—Lovastatin—atherosclerosis	0.000596	0.0032	CcSEcCtD
Ondansetron—Anxiety—Lovastatin—atherosclerosis	0.000594	0.00318	CcSEcCtD
Ondansetron—Flatulence—Niacin—atherosclerosis	0.000593	0.00318	CcSEcCtD
Ondansetron—Malaise—Simvastatin—atherosclerosis	0.000591	0.00317	CcSEcCtD
Ondansetron—Discomfort—Lovastatin—atherosclerosis	0.000589	0.00316	CcSEcCtD
Ondansetron—Chest pain—Ezetimibe—atherosclerosis	0.000585	0.00313	CcSEcCtD
Ondansetron—Flatulence—Pravastatin—atherosclerosis	0.000584	0.00313	CcSEcCtD
Ondansetron—Dry mouth—Lovastatin—atherosclerosis	0.000583	0.00313	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000581	0.00311	CcSEcCtD
Ondansetron—Discomfort—Ezetimibe—atherosclerosis	0.000578	0.0031	CcSEcCtD
Ondansetron—Constipation—Rosuvastatin—atherosclerosis	0.000577	0.00309	CcSEcCtD
Ondansetron—Pain—Rosuvastatin—atherosclerosis	0.000577	0.00309	CcSEcCtD
Ondansetron—Dry mouth—Ezetimibe—atherosclerosis	0.000572	0.00307	CcSEcCtD
Ondansetron—Anaphylactic shock—Lovastatin—atherosclerosis	0.000572	0.00306	CcSEcCtD
Ondansetron—Vision blurred—Niacin—atherosclerosis	0.000567	0.00304	CcSEcCtD
Ondansetron—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000561	0.003	CcSEcCtD
Ondansetron—Vision blurred—Pravastatin—atherosclerosis	0.000558	0.00299	CcSEcCtD
Ondansetron—Chest pain—Simvastatin—atherosclerosis	0.000558	0.00299	CcSEcCtD
Ondansetron—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000556	0.00298	CcSEcCtD
Ondansetron—Anxiety—Simvastatin—atherosclerosis	0.000556	0.00298	CcSEcCtD
Ondansetron—Tremor—Pravastatin—atherosclerosis	0.000555	0.00297	CcSEcCtD
Ondansetron—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000552	0.00296	CcSEcCtD
Ondansetron—Discomfort—Simvastatin—atherosclerosis	0.000551	0.00295	CcSEcCtD
Ondansetron—Nervous system disorder—Ezetimibe—atherosclerosis	0.00055	0.00295	CcSEcCtD
Ondansetron—Angioedema—Niacin—atherosclerosis	0.00055	0.00295	CcSEcCtD
Ondansetron—Ill-defined disorder—Pravastatin—atherosclerosis	0.00055	0.00295	CcSEcCtD
Ondansetron—Skin disorder—Ezetimibe—atherosclerosis	0.000545	0.00292	CcSEcCtD
Ondansetron—Angioedema—Pravastatin—atherosclerosis	0.000541	0.0029	CcSEcCtD
Ondansetron—Syncope—Niacin—atherosclerosis	0.00054	0.00289	CcSEcCtD
Ondansetron—Urticaria—Rosuvastatin—atherosclerosis	0.000536	0.00287	CcSEcCtD
Ondansetron—Anaphylactic shock—Simvastatin—atherosclerosis	0.000535	0.00287	CcSEcCtD
Ondansetron—Malaise—Pravastatin—atherosclerosis	0.000534	0.00286	CcSEcCtD
Ondansetron—Abdominal pain—Rosuvastatin—atherosclerosis	0.000533	0.00286	CcSEcCtD
Ondansetron—Palpitations—Niacin—atherosclerosis	0.000532	0.00285	CcSEcCtD
Ondansetron—Loss of consciousness—Niacin—atherosclerosis	0.000529	0.00283	CcSEcCtD
Ondansetron—Cough—Niacin—atherosclerosis	0.000525	0.00281	CcSEcCtD
Ondansetron—Cough—Pravastatin—atherosclerosis	0.000517	0.00277	CcSEcCtD
Ondansetron—Paraesthesia—Lovastatin—atherosclerosis	0.000513	0.00275	CcSEcCtD
Ondansetron—Dyspnoea—Lovastatin—atherosclerosis	0.00051	0.00273	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000509	0.00273	CcSEcCtD
Ondansetron—Chest pain—Pravastatin—atherosclerosis	0.000504	0.0027	CcSEcCtD
Ondansetron—Paraesthesia—Ezetimibe—atherosclerosis	0.000504	0.0027	CcSEcCtD
Ondansetron—Anxiety—Pravastatin—atherosclerosis	0.000503	0.00269	CcSEcCtD
Ondansetron—Dry mouth—Niacin—atherosclerosis	0.000501	0.00268	CcSEcCtD
Ondansetron—Dyspnoea—Ezetimibe—atherosclerosis	0.0005	0.00268	CcSEcCtD
Ondansetron—Discomfort—Pravastatin—atherosclerosis	0.000498	0.00267	CcSEcCtD
Ondansetron—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000497	0.00266	CcSEcCtD
Ondansetron—Fatigue—Lovastatin—atherosclerosis	0.000493	0.00264	CcSEcCtD
Ondansetron—Anaphylactic shock—Niacin—atherosclerosis	0.000491	0.00263	CcSEcCtD
Ondansetron—Pain—Lovastatin—atherosclerosis	0.000489	0.00262	CcSEcCtD
Ondansetron—Constipation—Lovastatin—atherosclerosis	0.000489	0.00262	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000484	0.00259	CcSEcCtD
Ondansetron—Asthenia—Rosuvastatin—atherosclerosis	0.000484	0.00259	CcSEcCtD
Ondansetron—Anaphylactic shock—Pravastatin—atherosclerosis	0.000484	0.00259	CcSEcCtD
Ondansetron—Fatigue—Ezetimibe—atherosclerosis	0.000484	0.00259	CcSEcCtD
Ondansetron—Shock—Niacin—atherosclerosis	0.000483	0.00259	CcSEcCtD
Ondansetron—Paraesthesia—Simvastatin—atherosclerosis	0.00048	0.00257	CcSEcCtD
Ondansetron—Constipation—Ezetimibe—atherosclerosis	0.00048	0.00257	CcSEcCtD
Ondansetron—Pain—Ezetimibe—atherosclerosis	0.00048	0.00257	CcSEcCtD
Ondansetron—Tachycardia—Niacin—atherosclerosis	0.000479	0.00257	CcSEcCtD
Ondansetron—Pruritus—Rosuvastatin—atherosclerosis	0.000477	0.00256	CcSEcCtD
Ondansetron—Skin disorder—Niacin—atherosclerosis	0.000477	0.00256	CcSEcCtD
Ondansetron—Dyspnoea—Simvastatin—atherosclerosis	0.000477	0.00255	CcSEcCtD
Ondansetron—Feeling abnormal—Lovastatin—atherosclerosis	0.000471	0.00252	CcSEcCtD
Ondansetron—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000468	0.00251	CcSEcCtD
Ondansetron—Feeling abnormal—Ezetimibe—atherosclerosis	0.000462	0.00248	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000462	0.00247	CcSEcCtD
Ondansetron—Diarrhoea—Rosuvastatin—atherosclerosis	0.000462	0.00247	CcSEcCtD
Ondansetron—Fatigue—Simvastatin—atherosclerosis	0.000461	0.00247	CcSEcCtD
Ondansetron—Hypotension—Niacin—atherosclerosis	0.000459	0.00246	CcSEcCtD
Ondansetron—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000459	0.00246	CcSEcCtD
Ondansetron—Constipation—Simvastatin—atherosclerosis	0.000457	0.00245	CcSEcCtD
Ondansetron—Pain—Simvastatin—atherosclerosis	0.000457	0.00245	CcSEcCtD
Ondansetron—Urticaria—Lovastatin—atherosclerosis	0.000454	0.00243	CcSEcCtD
Ondansetron—Body temperature increased—Lovastatin—atherosclerosis	0.000452	0.00242	CcSEcCtD
Ondansetron—Abdominal pain—Lovastatin—atherosclerosis	0.000452	0.00242	CcSEcCtD
Ondansetron—Dizziness—Rosuvastatin—atherosclerosis	0.000446	0.00239	CcSEcCtD
Ondansetron—Urticaria—Ezetimibe—atherosclerosis	0.000446	0.00239	CcSEcCtD
Ondansetron—Abdominal pain—Ezetimibe—atherosclerosis	0.000443	0.00238	CcSEcCtD
Ondansetron—Body temperature increased—Ezetimibe—atherosclerosis	0.000443	0.00238	CcSEcCtD
Ondansetron—Paraesthesia—Niacin—atherosclerosis	0.000441	0.00236	CcSEcCtD
Ondansetron—Feeling abnormal—Simvastatin—atherosclerosis	0.000441	0.00236	CcSEcCtD
Ondansetron—Dyspnoea—Niacin—atherosclerosis	0.000438	0.00235	CcSEcCtD
Ondansetron—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000437	0.00234	CcSEcCtD
Ondansetron—Somnolence—Niacin—atherosclerosis	0.000437	0.00234	CcSEcCtD
Ondansetron—Paraesthesia—Pravastatin—atherosclerosis	0.000434	0.00233	CcSEcCtD
Ondansetron—Dyspnoea—Pravastatin—atherosclerosis	0.000431	0.00231	CcSEcCtD
Ondansetron—Rash—Rosuvastatin—atherosclerosis	0.000425	0.00228	CcSEcCtD
Ondansetron—Dermatitis—Rosuvastatin—atherosclerosis	0.000425	0.00228	CcSEcCtD
Ondansetron—Urticaria—Simvastatin—atherosclerosis	0.000425	0.00228	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Niacin—atherosclerosis	0.000424	0.00227	CcSEcCtD
Ondansetron—Body temperature increased—Simvastatin—atherosclerosis	0.000423	0.00227	CcSEcCtD
Ondansetron—Abdominal pain—Simvastatin—atherosclerosis	0.000423	0.00227	CcSEcCtD
Ondansetron—Headache—Rosuvastatin—atherosclerosis	0.000423	0.00226	CcSEcCtD
Ondansetron—Hypersensitivity—Lovastatin—atherosclerosis	0.000421	0.00226	CcSEcCtD
Ondansetron—Pain—Niacin—atherosclerosis	0.00042	0.00225	CcSEcCtD
Ondansetron—Fatigue—Pravastatin—atherosclerosis	0.000417	0.00223	CcSEcCtD
Ondansetron—Pain—Pravastatin—atherosclerosis	0.000414	0.00222	CcSEcCtD
Ondansetron—Constipation—Pravastatin—atherosclerosis	0.000414	0.00222	CcSEcCtD
Ondansetron—Hypersensitivity—Ezetimibe—atherosclerosis	0.000413	0.00221	CcSEcCtD
Ondansetron—Asthenia—Lovastatin—atherosclerosis	0.00041	0.0022	CcSEcCtD
Ondansetron—Pruritus—Lovastatin—atherosclerosis	0.000405	0.00217	CcSEcCtD
Ondansetron—Asthenia—Ezetimibe—atherosclerosis	0.000402	0.00216	CcSEcCtD
Ondansetron—Gastrointestinal pain—Niacin—atherosclerosis	0.000402	0.00215	CcSEcCtD
Ondansetron—Feeling abnormal—Pravastatin—atherosclerosis	0.000398	0.00213	CcSEcCtD
Ondansetron—Pruritus—Ezetimibe—atherosclerosis	0.000397	0.00213	CcSEcCtD
Ondansetron—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000395	0.00212	CcSEcCtD
Ondansetron—Hypersensitivity—Simvastatin—atherosclerosis	0.000394	0.00211	CcSEcCtD
Ondansetron—Diarrhoea—Lovastatin—atherosclerosis	0.000391	0.0021	CcSEcCtD
Ondansetron—Urticaria—Niacin—atherosclerosis	0.00039	0.00209	CcSEcCtD
Ondansetron—Body temperature increased—Niacin—atherosclerosis	0.000388	0.00208	CcSEcCtD
Ondansetron—Abdominal pain—Niacin—atherosclerosis	0.000388	0.00208	CcSEcCtD
Ondansetron—Urticaria—Pravastatin—atherosclerosis	0.000384	0.00206	CcSEcCtD
Ondansetron—Asthenia—Simvastatin—atherosclerosis	0.000384	0.00206	CcSEcCtD
Ondansetron—Diarrhoea—Ezetimibe—atherosclerosis	0.000384	0.00206	CcSEcCtD
Ondansetron—Abdominal pain—Pravastatin—atherosclerosis	0.000382	0.00205	CcSEcCtD
Ondansetron—Body temperature increased—Pravastatin—atherosclerosis	0.000382	0.00205	CcSEcCtD
Ondansetron—Pruritus—Simvastatin—atherosclerosis	0.000378	0.00203	CcSEcCtD
Ondansetron—Dizziness—Lovastatin—atherosclerosis	0.000378	0.00203	CcSEcCtD
Ondansetron—Dizziness—Ezetimibe—atherosclerosis	0.000371	0.00199	CcSEcCtD
Ondansetron—Diarrhoea—Simvastatin—atherosclerosis	0.000366	0.00196	CcSEcCtD
Ondansetron—Vomiting—Lovastatin—atherosclerosis	0.000364	0.00195	CcSEcCtD
Ondansetron—Hypersensitivity—Niacin—atherosclerosis	0.000362	0.00194	CcSEcCtD
Ondansetron—Rash—Lovastatin—atherosclerosis	0.000361	0.00193	CcSEcCtD
Ondansetron—Dermatitis—Lovastatin—atherosclerosis	0.00036	0.00193	CcSEcCtD
Ondansetron—Headache—Lovastatin—atherosclerosis	0.000358	0.00192	CcSEcCtD
Ondansetron—Vomiting—Ezetimibe—atherosclerosis	0.000357	0.00191	CcSEcCtD
Ondansetron—Hypersensitivity—Pravastatin—atherosclerosis	0.000356	0.00191	CcSEcCtD
Ondansetron—Dizziness—Simvastatin—atherosclerosis	0.000354	0.00189	CcSEcCtD
Ondansetron—Rash—Ezetimibe—atherosclerosis	0.000354	0.00189	CcSEcCtD
Ondansetron—Dermatitis—Ezetimibe—atherosclerosis	0.000353	0.00189	CcSEcCtD
Ondansetron—Asthenia—Niacin—atherosclerosis	0.000352	0.00189	CcSEcCtD
Ondansetron—Headache—Ezetimibe—atherosclerosis	0.000351	0.00188	CcSEcCtD
Ondansetron—Pruritus—Niacin—atherosclerosis	0.000347	0.00186	CcSEcCtD
Ondansetron—Asthenia—Pravastatin—atherosclerosis	0.000347	0.00186	CcSEcCtD
Ondansetron—Pruritus—Pravastatin—atherosclerosis	0.000342	0.00183	CcSEcCtD
Ondansetron—Vomiting—Simvastatin—atherosclerosis	0.00034	0.00182	CcSEcCtD
Ondansetron—Rash—Simvastatin—atherosclerosis	0.000337	0.00181	CcSEcCtD
Ondansetron—Dermatitis—Simvastatin—atherosclerosis	0.000337	0.00181	CcSEcCtD
Ondansetron—Diarrhoea—Niacin—atherosclerosis	0.000336	0.0018	CcSEcCtD
Ondansetron—Headache—Simvastatin—atherosclerosis	0.000335	0.0018	CcSEcCtD
Ondansetron—Diarrhoea—Pravastatin—atherosclerosis	0.000331	0.00177	CcSEcCtD
Ondansetron—Dizziness—Niacin—atherosclerosis	0.000325	0.00174	CcSEcCtD
Ondansetron—Dizziness—Pravastatin—atherosclerosis	0.00032	0.00171	CcSEcCtD
Ondansetron—Vomiting—Niacin—atherosclerosis	0.000312	0.00167	CcSEcCtD
Ondansetron—Rash—Niacin—atherosclerosis	0.00031	0.00166	CcSEcCtD
Ondansetron—Dermatitis—Niacin—atherosclerosis	0.000309	0.00166	CcSEcCtD
Ondansetron—Headache—Niacin—atherosclerosis	0.000308	0.00165	CcSEcCtD
Ondansetron—Vomiting—Pravastatin—atherosclerosis	0.000307	0.00165	CcSEcCtD
Ondansetron—Rash—Pravastatin—atherosclerosis	0.000305	0.00163	CcSEcCtD
Ondansetron—Dermatitis—Pravastatin—atherosclerosis	0.000305	0.00163	CcSEcCtD
Ondansetron—Headache—Pravastatin—atherosclerosis	0.000303	0.00162	CcSEcCtD
Ondansetron—CYP3A7—Metabolism—CAV1—atherosclerosis	1.1e-05	0.00011	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOC3—atherosclerosis	1.1e-05	0.00011	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.1e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	1.1e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—APOA1—atherosclerosis	1.1e-05	0.000109	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL6—atherosclerosis	1.1e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—LDLR—atherosclerosis	1.09e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.09e-05	0.000108	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PRKCG—atherosclerosis	1.08e-05	0.000108	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APOE—atherosclerosis	1.08e-05	0.000108	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—LEP—atherosclerosis	1.08e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CETP—atherosclerosis	1.08e-05	0.000107	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.08e-05	0.000107	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.08e-05	0.000107	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CAV1—atherosclerosis	1.07e-05	0.000107	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CETP—atherosclerosis	1.07e-05	0.000106	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APOA1—atherosclerosis	1.07e-05	0.000106	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALOX5—atherosclerosis	1.06e-05	0.000106	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—MAPK3—atherosclerosis	1.06e-05	0.000105	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SPP1—atherosclerosis	1.05e-05	0.000105	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HMOX1—atherosclerosis	1.05e-05	0.000105	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL8—atherosclerosis	1.05e-05	0.000104	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HMOX1—atherosclerosis	1.05e-05	0.000104	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—INS—atherosclerosis	1.05e-05	0.000104	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.03e-05	0.000103	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ESR1—atherosclerosis	1.03e-05	0.000103	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCL2—atherosclerosis	1.03e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SCARB1—atherosclerosis	1.02e-05	0.000102	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—F2—atherosclerosis	1.02e-05	0.000101	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.02e-05	0.000101	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IGF1—atherosclerosis	1.01e-05	0.000101	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—atherosclerosis	1.01e-05	0.0001	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOB—atherosclerosis	1.01e-05	0.0001	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOB—atherosclerosis	1e-05	9.99e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CG—atherosclerosis	1e-05	9.99e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	9.97e-06	9.92e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	9.82e-06	9.76e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTM1—atherosclerosis	9.79e-06	9.74e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTM1—atherosclerosis	9.77e-06	9.72e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CG—atherosclerosis	9.76e-06	9.71e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	9.76e-06	9.71e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HMGCR—atherosclerosis	9.75e-06	9.7e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPARG—atherosclerosis	9.69e-06	9.64e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HMGCR—atherosclerosis	9.67e-06	9.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOA2—atherosclerosis	9.64e-06	9.59e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	9.64e-06	9.59e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	9.64e-06	9.59e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALOX15—atherosclerosis	9.64e-06	9.59e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	9.62e-06	9.57e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—LPL—atherosclerosis	9.61e-06	9.56e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—LPL—atherosclerosis	9.59e-06	9.54e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NAMPT—atherosclerosis	9.53e-06	9.48e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AGT—atherosclerosis	9.53e-06	9.48e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCG5—atherosclerosis	9.53e-06	9.48e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—INS—atherosclerosis	9.5e-06	9.45e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	9.47e-06	9.42e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—LIPC—atherosclerosis	9.47e-06	9.42e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOC3—atherosclerosis	9.41e-06	9.36e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GPX1—atherosclerosis	9.38e-06	9.33e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GPX1—atherosclerosis	9.36e-06	9.31e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—LDLR—atherosclerosis	9.35e-06	9.31e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK3—atherosclerosis	9.35e-06	9.3e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—LEP—atherosclerosis	9.34e-06	9.29e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APOE—atherosclerosis	9.34e-06	9.29e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CAV1—atherosclerosis	9.25e-06	9.2e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—INS—atherosclerosis	9.24e-06	9.19e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APOA1—atherosclerosis	9.23e-06	9.18e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LPA—atherosclerosis	9.2e-06	9.15e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NOS3—atherosclerosis	9.18e-06	9.13e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CETP—atherosclerosis	9.14e-06	9.09e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CD36—atherosclerosis	9.13e-06	9.09e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CD36—atherosclerosis	9.12e-06	9.07e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL2—atherosclerosis	9.09e-06	9.04e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1—atherosclerosis	8.94e-06	8.89e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ESR1—atherosclerosis	8.91e-06	8.87e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—BGN—atherosclerosis	8.91e-06	8.86e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOA5—atherosclerosis	8.82e-06	8.77e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—F2—atherosclerosis	8.8e-06	8.76e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SCARB1—atherosclerosis	8.75e-06	8.7e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.72e-06	8.68e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALB—atherosclerosis	8.71e-06	8.67e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ABCA1—atherosclerosis	8.69e-06	8.65e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MTHFR—atherosclerosis	8.66e-06	8.61e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MTHFR—atherosclerosis	8.64e-06	8.59e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ABCA1—atherosclerosis	8.62e-06	8.57e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	8.52e-06	8.47e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARA—atherosclerosis	8.49e-06	8.45e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	8.49e-06	8.45e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SERPINE1—atherosclerosis	8.49e-06	8.44e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARA—atherosclerosis	8.47e-06	8.43e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	8.43e-06	8.38e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NOS3—atherosclerosis	8.33e-06	8.29e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HMGCR—atherosclerosis	8.26e-06	8.22e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AGT—atherosclerosis	8.22e-06	8.18e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AGT—atherosclerosis	8.21e-06	8.16e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALOX5—atherosclerosis	8.2e-06	8.16e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	8.14e-06	8.1e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NOS3—atherosclerosis	8.1e-06	8.06e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	8.07e-06	8.03e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOE—atherosclerosis	8.06e-06	8.02e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOE—atherosclerosis	8.04e-06	8e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CAV1—atherosclerosis	7.98e-06	7.94e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—INS—atherosclerosis	7.98e-06	7.93e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CAV1—atherosclerosis	7.97e-06	7.93e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOA1—atherosclerosis	7.97e-06	7.92e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOA1—atherosclerosis	7.95e-06	7.91e-05	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	7.87e-06	7.83e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL2—atherosclerosis	7.85e-06	7.81e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—atherosclerosis	7.74e-06	7.7e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1—atherosclerosis	7.71e-06	7.67e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—atherosclerosis	7.62e-06	7.58e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HMOX1—atherosclerosis	7.46e-06	7.42e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.45e-06	7.41e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HMOX1—atherosclerosis	7.39e-06	7.36e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—atherosclerosis	7.37e-06	7.33e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ABCA1—atherosclerosis	7.36e-06	7.33e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NAMPT—atherosclerosis	7.36e-06	7.32e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	7.33e-06	7.29e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LIPC—atherosclerosis	7.31e-06	7.27e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	7.29e-06	7.25e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CG—atherosclerosis	7.27e-06	7.23e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOC3—atherosclerosis	7.26e-06	7.23e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CG—atherosclerosis	7.26e-06	7.22e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LDLR—atherosclerosis	7.22e-06	7.18e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—atherosclerosis	7.19e-06	7.15e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	7.16e-06	7.13e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	7.14e-06	7.11e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOB—atherosclerosis	7.14e-06	7.11e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOB—atherosclerosis	7.08e-06	7.05e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CETP—atherosclerosis	7.05e-06	7.01e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—atherosclerosis	7.02e-06	6.98e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—atherosclerosis	7e-06	6.97e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOS3—atherosclerosis	6.99e-06	6.96e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—atherosclerosis	6.95e-06	6.91e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—atherosclerosis	6.94e-06	6.91e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—atherosclerosis	6.89e-06	6.85e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—INS—atherosclerosis	6.88e-06	6.85e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—INS—atherosclerosis	6.87e-06	6.83e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—atherosclerosis	6.83e-06	6.8e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—LPL—atherosclerosis	6.82e-06	6.79e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—LPL—atherosclerosis	6.76e-06	6.73e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.75e-06	6.72e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GPX1—atherosclerosis	6.66e-06	6.62e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	6.61e-06	6.58e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GPX1—atherosclerosis	6.6e-06	6.56e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—atherosclerosis	6.55e-06	6.52e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—atherosclerosis	6.5e-06	6.47e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CD36—atherosclerosis	6.48e-06	6.45e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NFKB1—atherosclerosis	6.43e-06	6.4e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CD36—atherosclerosis	6.43e-06	6.39e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HMGCR—atherosclerosis	6.38e-06	6.34e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK8—atherosclerosis	6.32e-06	6.29e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HMOX1—atherosclerosis	6.32e-06	6.29e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—atherosclerosis	6.31e-06	6.28e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—atherosclerosis	6.31e-06	6.27e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—atherosclerosis	6.3e-06	6.27e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	6.26e-06	6.22e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	6.2e-06	6.17e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MTHFR—atherosclerosis	6.14e-06	6.11e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MTHFR—atherosclerosis	6.09e-06	6.06e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	6.07e-06	6.04e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOB—atherosclerosis	6.05e-06	6.02e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NOS3—atherosclerosis	6.04e-06	6.01e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARA—atherosclerosis	6.03e-06	5.99e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NOS3—atherosclerosis	6.02e-06	5.99e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	5.99e-06	5.96e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARA—atherosclerosis	5.97e-06	5.94e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—atherosclerosis	5.9e-06	5.87e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—atherosclerosis	5.89e-06	5.86e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—atherosclerosis	5.84e-06	5.81e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AGT—atherosclerosis	5.84e-06	5.81e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AGT—atherosclerosis	5.79e-06	5.76e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—atherosclerosis	5.78e-06	5.75e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—LPL—atherosclerosis	5.78e-06	5.75e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOE—atherosclerosis	5.72e-06	5.69e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.68e-06	5.65e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOE—atherosclerosis	5.67e-06	5.64e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CAV1—atherosclerosis	5.67e-06	5.64e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOA1—atherosclerosis	5.65e-06	5.62e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GPX1—atherosclerosis	5.64e-06	5.61e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CAV1—atherosclerosis	5.62e-06	5.59e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—atherosclerosis	5.61e-06	5.58e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOA1—atherosclerosis	5.6e-06	5.57e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	5.55e-06	5.52e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK3—atherosclerosis	5.52e-06	5.49e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—atherosclerosis	5.52e-06	5.49e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—atherosclerosis	5.51e-06	5.48e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CD36—atherosclerosis	5.49e-06	5.46e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	5.46e-06	5.43e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	5.44e-06	5.41e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFB1—atherosclerosis	5.36e-06	5.33e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MTHFR—atherosclerosis	5.2e-06	5.18e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CG—atherosclerosis	5.16e-06	5.13e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CG—atherosclerosis	5.12e-06	5.09e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARA—atherosclerosis	5.1e-06	5.08e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	5.04e-06	5.01e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—atherosclerosis	4.99e-06	4.96e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—atherosclerosis	4.98e-06	4.95e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AGT—atherosclerosis	4.94e-06	4.92e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—atherosclerosis	4.94e-06	4.91e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—INS—atherosclerosis	4.89e-06	4.86e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.88e-06	4.85e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOE—atherosclerosis	4.84e-06	4.82e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—INS—atherosclerosis	4.84e-06	4.82e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CAV1—atherosclerosis	4.8e-06	4.77e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOA1—atherosclerosis	4.79e-06	4.76e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	4.77e-06	4.74e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOB—atherosclerosis	4.67e-06	4.65e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	4.63e-06	4.6e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—atherosclerosis	4.57e-06	4.55e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.54e-06	4.52e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—atherosclerosis	4.48e-06	4.45e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LPL—atherosclerosis	4.46e-06	4.44e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—atherosclerosis	4.44e-06	4.42e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CG—atherosclerosis	4.37e-06	4.35e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GPX1—atherosclerosis	4.35e-06	4.33e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NOS3—atherosclerosis	4.28e-06	4.26e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NOS3—atherosclerosis	4.25e-06	4.22e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CD36—atherosclerosis	4.24e-06	4.22e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—atherosclerosis	4.22e-06	4.2e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—atherosclerosis	4.22e-06	4.2e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—INS—atherosclerosis	4.14e-06	4.12e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—atherosclerosis	4.04e-06	4.02e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTHFR—atherosclerosis	4.02e-06	3.99e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARA—atherosclerosis	3.94e-06	3.92e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.92e-06	3.9e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—atherosclerosis	3.88e-06	3.86e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—atherosclerosis	3.83e-06	3.81e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AGT—atherosclerosis	3.82e-06	3.8e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—atherosclerosis	3.79e-06	3.77e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOE—atherosclerosis	3.74e-06	3.72e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—atherosclerosis	3.72e-06	3.71e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CAV1—atherosclerosis	3.7e-06	3.68e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOA1—atherosclerosis	3.7e-06	3.68e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NOS3—atherosclerosis	3.63e-06	3.61e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—atherosclerosis	3.49e-06	3.47e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.37e-06	3.36e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—atherosclerosis	3.32e-06	3.3e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—atherosclerosis	3.26e-06	3.24e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—atherosclerosis	3.22e-06	3.2e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—INS—atherosclerosis	3.19e-06	3.18e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—atherosclerosis	2.93e-06	2.91e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NOS3—atherosclerosis	2.8e-06	2.79e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—atherosclerosis	2.78e-06	2.76e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—atherosclerosis	2.77e-06	2.75e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.56e-06	2.55e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—atherosclerosis	1.97e-06	1.96e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—atherosclerosis	1.95e-06	1.94e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—atherosclerosis	1.67e-06	1.66e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—atherosclerosis	1.29e-06	1.28e-05	CbGpPWpGaD
